FONR vs IMDX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
FONR presents as a classic value play with a stable Piotroski F-Score of 4/9 and a current price ($18.61) trading significantly below its Graham Number ($26.43). The company maintains an exceptionally strong balance sheet with a Current Ratio of 10.00 and very low debt (D/E 0.24), providing a massive safety cushion. However, this financial stability is offset by stagnant growth metrics, with YoY earnings growth of only 1.10%, and a bearish technical trend (10/100). Ultimately, the stock appears to be a low-risk, low-reward 'value trap' unless a growth catalyst emerges.
IMDX exhibits severe financial distress, anchored by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from negative equity (Price/Book: -2.89) and a catastrophic operating margin of -873.57%, suggesting an unsustainable business model. Revenue is contracting rapidly (-23.4% YoY), and the earnings track record is abysmal with 0 beats in the last four quarters. Despite optimistic analyst price targets, the deterministic data points toward a high risk of insolvency or significant further dilution.
Compare Another Pair
Related Comparisons
FONR vs IMDX: Head-to-Head Comparison
This page compares FONAR Corporation (FONR) and Insight Molecular Diagnostics Inc. (IMDX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.